Amgen Inc. stock price, AMGN

Amgen Inc. stock chart:



Amgen Inc. close price: 160.22

Stock price forecast:

UP TO +3.20%
Target: 165.34

Total forecasts: 82
Reached: 25 (30.49%)

Total Win: 126.24 (71.78%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%
90832530.12%126.240.86%9,633.56292.023.03%418.263.03%
3031516.13%4.580.09%4,190.11-24.39-0.58%-19.81-0.40%
141500.00%0.000.00%2,403.300.000.00%0.000.00%
7800.00%0.000.00%1,281.760.000.00%0.000.00%

Showing 1-10 of 567 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date
2017-05-29160.22165.410000-00-00
2017-05-28160.22165.310000-00-00
2017-05-27160.22165.310000-00-00
2017-05-26160.22164.970000-00-00
2017-05-25160.22164.970000-00-00
2017-05-24160.22164.830000-00-00
2017-05-23160.22164.460000-00-00
2017-05-22160.22165.150000-00-00
2017-05-21160.22164.050000-00-00
2017-05-20160.22164.050000-00-00

Amgen Inc. latest news:


  • 05/22/2017 08:28:32

    UPDATE: Amgen Inc. stock drops 2% on drug's cardiovascular risk; no approval expected this year

    Amgen Inc. shares dropped 1.9% in morning trade Monday after the company said that it has observed new cardiovascular risks for its Evenity drug, which is intended to reduce risk of fractures in patients with osteoporosis, and that it does not expect the drug to get approved this year. Shares of its partner on the drug, UCB , declined 17.9%. Amgen said it saw this new cardiovascular safety signal in its late-stage trial for the drug, with Evenity having an imbalance in serious cardiovascular adverse events as compared with the current standard of care in osteoporosis, alendronate. Sean Harper, Amgen's executive vice president of research and development, said that "the newly observed cardiovascular safety signal will have to be assessed as part of the overall benefit:risk profile for Evenity" and that it would work with UCB to evaluate the data with global regulators and medical experts. The latest results are "clearly negative, and very surprising," said EvercoreISI analyst Umer Raffat. The clinical trial met its two primary endpoints and its key secondary endpoint, Amgen also said. Amgen shares have dropped 11.1% over the last three months, and UCB shares have declined 8.2%, compared with a 1.1% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 05/21/2017 18:56:28

    Higher rate of heart problems seen with Amgen bone drug in trial

    Amgen Inc(AMGN) and UCB SA said on Sunday they did not expect their experimental osteoporosis drug to win U.S. approval this year after a higher rate of serious heart-related side effects were observed in a late-stage clinical trial. The drug, romosozumab, which would be sold under the brand name Evenity if approved, is awaiting an approval decision by the Food and Drug Administration.

  • 05/21/2017 18:56:02

    UPDATE 2-Higher rate of heart problems seen with Amgen bone drug in trial

    May 21 (Reuters) - Amgen Inc and UCB SA said on Sunday they did not expect their experimental osteoporosis drug to win U.S. approval this year after a higher rate of serious heart-related side effects were observed in a late-stage clinical trial.

  • 04/26/2017 16:31:43

    BRIEF-Amgen reports Q1 GAAP earnings per share $2.79

    * Says 2017 earnings per share guidance increased to $10.64-$11.32 on GAAP basis, and $12.00-$12.60 on non-GAAP basis

  • 04/26/2017 15:09:34

    Cost controls help offset lower Amgen first-quarter drug sales

    (Reuters) - Amgen Inc on Wednesday reported higher-than-expected first-quarter profit as cost controls helped offset a sharp drop in sales of Enbrel, its blockbuster rheumatoid arthritis and psoriasis drug.

  • 04/26/2017 14:21:19

    Amgen shares slide on weak Enbrel sales

    Shares of Amgen Inc. slid in Wednesday's extended session after the biopharmaceutical company reported a double-digit sales decline of its blockbuster drug. Amgen reported its first-quarter earnings rose to $2.07 billion, or $2.79 a share, from $1.9 billion, or $2.50 a share, a year earlier. On an adjusted basis, the pharmaceutical giant would have earned $3.15 a share. Revenue slipped 1% to $5.46 billion. Analysts surveyed by FactSet had forecast earnings of $2.99 a share on revenue of $5.61 billion. Amgen also said that sales of its rheumatoid arthritis and plaque psoriasis drug Enbrel fell 15% due to increased competition. The drug maker kept its 2017 revenue outlook unchanged at $22.3 billion to $23.1 billion but raised the lower end of its adjusted earnings per share forecast to a range of $12 to $12.60. It had previously projected $11.80 to $12.60. Amgen shares dropped 2.9% after hours. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 04/26/2017 14:12:48

    Amgen first-quarter profit exceeds Street estimates on lower costs

    (Reuters) - Amgen Inc on Wednesday reported higher-than-expected first-quarter profit as cost controls helped offset a sharp drop in sales of Enbrel, its blockbuster rheumatoid arthritis and psoriasis drug.

  • 04/06/2017 14:31:52

    BRIEF-Amgen says CEO Robert Bradway's total compensation for 2016 was $16.9 mln vs $16.1 mln in 2015 - SEC filing

    * Amgen Inc - CEO Robert Bradway's total compensation for 2016 was $16.9 million versus $16.1 million in 2015 - SEC filing Source text: (http://bit.ly/2oOpF0j) Further company coverage:

  • 03/17/2017 14:31:25

    Wall St. flat as banks, Amgen weigh; Adobe rallies

    NEW YORK (Reuters) - U.S. stocks dipped on Friday as bank shares fell alongside Treasury yields while Adobe helped buoy the S&P tech sector and the Nasdaq Composite.

  • 03/17/2017 08:05:32

    Wall Street little changed as healthcare stocks weigh

    (Reuters) - U.S. stocks were little changed on Friday as a slide in Amgen dragged down the healthcare sector, offsetting gains in technology shares.

  • 03/12/2017 23:00:00

    Data on heart benefits of Amgen drug is key to unlocking sales

    March 13 (Reuters) - Data that should help unlock the sales potential of a potent new cholesterol medicine will be unveiled at the American College of Cardiology meeting this week as the future of the only rival drug rests with the courts in an ongoing patent dispute.

  • 03/06/2017 06:41:21

    Advaxis stock jumps 10% after FDA okays clinical trials for Amgen-partnered cancer drug

    Advaxis Inc. shares surged 10.6% in pre-market trade Monday after the company said the Food and Drug Administration would allow its ADXS-NEO, a cancer immunotherapy drug partnership with Amgen , to proceed to clinical trials. ADXS-NEO's approach targets neoantigens, which are seen as a promising avenue of cancer drug development, and the drug is only the second of this type with an Investigational New Drug application accepted by the FDA, according to a company spokesperson. Advaxis said it plans to start a phase 1 trial for the drug in multiple tumor types later this year. Amgen shares slumped 0.2% in pre-market trade Monday. Shares of Advaxis have risen 3.5% over the last three months, and shares of Amgen have surged 24.2% over the last three months, compared with a 7.7% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Amicus Therapeutics, Inc.FOLD | Amkor Technology, Inc.AMKR | Amphastar Pharmaceuticals, Inc.AMPH | Amsurg Corp.AMSG | Amsurg Corp.AMSGP | Amtech Systems, Inc.ASYS | AmTrust Financial Services, Inc.AFSI+0.53% | Amyris, Inc.AMRS | Anacor Pharmaceuticals, Inc.ANAC | ANADIGICS, Inc.ANAD |